Deep, qualified upcoming-generation sequencing has disclosed that subclonal mutations (i.e., those existing in only a portion of tumor cells) can be detected for all driver genes and so are affiliated with quick disorder development and lousy outcome.11–13 This is particularly pertinent for TP53Cure for relapsed/refractory disease must be decided